Exact Sciences Reaches New 52-Week High

Analysts Weigh In on Whether the Stock Is Still a Buy

Published on Mar. 9, 2026

Got story updates? Submit your updates here. ›

Exact Sciences Corporation (NASDAQ:EXAS) saw its share price reach a new 52-week high of $103.75 on Monday, with the stock closing at $103.71. The company, which is known for its Cologuard colorectal cancer screening test, has seen its stock price rise significantly in recent months as analysts have issued new price targets and ratings.

Why it matters

Exact Sciences' strong stock performance reflects the growing demand for its Cologuard test, which provides a non-invasive option for colorectal cancer screening. As the company continues to expand its product portfolio and market reach, its stock could continue to be an attractive investment option for those looking to capitalize on the growth in the molecular diagnostics industry.

The details

Several research firms have recently issued reports on Exact Sciences, with Barclays reissuing an "equal weight" rating and increasing its price target to $105.00. Evercore also set a $105.00 price target on the stock, while William Blair downgraded it from "outperform" to "market perform." Overall, 21 investment analysts have rated the stock as a "Hold," with one giving it a "Sell" rating.

  • Exact Sciences' share price reached a new 52-week high on Monday, March 9, 2026.

The players

Exact Sciences Corporation

A molecular diagnostics company headquartered in Madison, Wisconsin, dedicated to the early detection and prevention of cancer. The company's flagship product is the Cologuard colorectal cancer screening test.

Barclays

A multinational investment bank that has reissued an "equal weight" rating and increased its price target for Exact Sciences.

Evercore

An independent investment banking advisory firm that has set a $105.00 price target for Exact Sciences.

William Blair

A global investment banking and asset management firm that has downgraded Exact Sciences from "outperform" to "market perform."

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee (Instagram)

The takeaway

Exact Sciences' strong stock performance and the positive analyst sentiment around the company's Cologuard test suggest that the stock could continue to be an attractive investment option for those looking to capitalize on the growth in the molecular diagnostics industry. However, the mixed ratings from analysts indicate that investors should closely monitor the company's performance and market trends before making any investment decisions.